Literature DB >> 28740535

Acute severe diarrhoea and hyponatremia after zoledronic acid infusion: an acute phase reaction.

Mohammad Shafi Kuchay1, Khalid Jamal Farooqui1, Ambrish Mithal1.   

Abstract

Zoledronic acid (ZA), an intravenous aminobisphosphonate, is prescribed widely for postmenopausal osteoporosis. It is a relatively safe drug but may cause adverse effects including acute phase reaction. Oral non-aminobisphosphonates are known to cause diarrhoea that is usually mild and self-limited. Intravenous amino-bisphosphonates are not known to cause diarrhoea. We describe a case of acute watery diarrhoea complicated by severe hyponatremia and hypotension following ZA infusion. The patient needed intensive care for four days. To the best of our knowledge, this type of acute diarrhoea complicated by severe hyponatremia, following ZA infusion, is not reported so far. Strong temporal relation with ZA administration makes it the most likely cause. Furthermore, all laboratory and imaging parameters indicate that the secretory diarrhoea may be a component of acute phase reaction. According to World Health Organization (WHO) causality scale, ZA was a probable cause of acute watery diarrhoea in our patient. Clinicians should be aware that ZA administration can cause acute watery diarrhoea and may lead to severe hypotension and hyponatremia.

Entities:  

Keywords:  acute severe diarrhoea; hyponatremia; hypotension; postmenopausal osteoporosis; zoledronic acid

Year:  2017        PMID: 28740535      PMCID: PMC5505705          DOI: 10.11138/ccmbm/2017.14.1.101

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  11 in total

1.  Electrolyte abnormalities with zoledronic acid therapy.

Authors:  Steven M Sorscher
Journal:  Cancer J       Date:  2002 Jul-Aug       Impact factor: 3.360

2.  Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate.

Authors:  Brett A Lenart; Dean G Lorich; Joseph M Lane
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

3.  Reports of esophageal cancer with oral bisphosphonate use.

Authors:  Diane K Wysowski
Journal:  N Engl J Med       Date:  2009-01-01       Impact factor: 91.245

4.  Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

Authors:  S P Luckman; D E Hughes; F P Coxon; R Graham; G Russell; M J Rogers
Journal:  J Bone Miner Res       Date:  1998-04       Impact factor: 6.741

5.  Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations.

Authors:  M Pecherstorfer; R Jilch; A Sauty; E Horn; A V Keck; I Zimmer-Roth; D Thiebaud
Journal:  J Bone Miner Res       Date:  2000-01       Impact factor: 6.741

6.  Lymphocyte subsets in pamidronate-induced lymphopenia.

Authors:  F Lioté; B Boval-Boizard; P Fritz; D Kuntz
Journal:  Br J Rheumatol       Date:  1995-10

7.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

8.  Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6.

Authors:  Giordano Dicuonzo; Bruno Vincenzi; Daniele Santini; Giuseppe Avvisati; Laura Rocci; Fabrizio Battistoni; Michele Gavasci; Domenico Borzomati; Roberto Coppola; Giuseppe Tonini
Journal:  J Interferon Cytokine Res       Date:  2003-11       Impact factor: 2.607

9.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

10.  Systemic mastocytosis involving the gastrointestinal tract: clinicopathologic and molecular study of five cases.

Authors:  Richard Kirsch; Karel Geboes; Neil A Shepherd; Gert de Hertogh; Nando Di Nicola; Sylvie Lebel; Ugnius Mickys; Robert H Riddell
Journal:  Mod Pathol       Date:  2008-10-17       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.